Holen Sie sich die Stockscreener-App
0.9299
0.53%
0.0049
Handel nachbörslich:
.93
0.0001
+0.01%
Schlusskurs vom Vortag:
$0.925
Offen:
$0.9316
24-Stunden-Volumen:
157.83K
Relative Volume:
0.46
Marktkapitalisierung:
$70.53M
Einnahmen:
$8.23M
Nettoeinkommen (Verlust:
$-32.49M
KGV:
-1.7545
EPS:
-0.53
Netto-Cashflow:
$-19.91M
1W Leistung:
-5.11%
1M Leistung:
-8.83%
6M Leistung:
-23.15%
1J Leistung:
-30.60%
1-Tages-Spanne:
$0.925
$0.9676
1-Wochen-Bereich:
$0.9011
$0.98
52-Wochen-Spanne:
$0.801
$2.12
Clearside Biomedical Inc Stock (CLSD) Company Profile
Firmenname
Clearside Biomedical Inc
Sektor
Branche
Telefon
678-270-3631
Adresse
900 NORTH POINT PARKWAY, ALPHARETTA, GA
Vergleichen Sie CLSD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.9299 | 70.53M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
422.00 | 108.68B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
681.58 | 74.90B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
640.52 | 38.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
246.27 | 31.76B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
111.93 | 26.83B | 3.30B | -501.07M | 1.03B | -2.1146 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-21 | Eingeleitet | Chardan Capital Markets | Buy |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2021-12-15 | Fortgesetzt | Wedbush | Outperform |
| 2021-07-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-05-13 | Eingeleitet | ROTH Capital | Buy |
| 2019-08-09 | Herabstufung | Needham | Buy → Hold |
| 2018-11-05 | Herabstufung | Cowen | Outperform → Market Perform |
| 2018-11-05 | Herabstufung | JP Morgan | Overweight → Underweight |
| 2018-11-05 | Herabstufung | Stifel | Buy → Hold |
| 2018-03-06 | Bestätigt | Needham | Buy |
| 2017-05-25 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2017-02-24 | Eingeleitet | JP Morgan | Overweight |
| 2016-11-10 | Bestätigt | Needham | Buy |
| 2016-10-24 | Bestätigt | Stifel | Buy |
Alle ansehen
Clearside Biomedical Inc Aktie (CLSD) Neueste Nachrichten
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Significant Decline in Short Interest - MarketBeat
Geode Capital Management LLC Buys 59,089 Shares of Clearside Biomedical, Inc. (NASDAQ:CLSD) - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives $5.33 Average Price Target from Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Average Rating of “Buy” by Analysts - Defense World
Clearside Biomedical (NASDAQ:CLSD) Stock Price Crosses Below 50-Day Moving Average – Here’s Why - Defense World
Clearside Biomedical (NASDAQ:CLSD) Shares Pass Below 50 Day Moving AverageWhat's Next? - MarketBeat
Further weakness as Clearside Biomedical (NASDAQ:CLSD) drops 14% this week, taking five-year losses to 72% - Simply Wall St
Clearside Biomedical stock hits 52-week low at $0.92 By Investing.com - Investing.com South Africa
Clearside Biomedical stock hits 52-week low at $0.92 - Investing.com
Clearside announces publication of insights on drug development, regulation - Yahoo Finance
Analyst Sees 500% Upside for This Pharmaceutical Penny Stock - GuruFocus.com
Clearside Biomedical Announces Publication of Critical - GlobeNewswire
Clearside Biomedical Unveils Groundbreaking Insights on Retinal Drug Development in Eye Journal - StockTitan
Clearside Biomedical, Inc. (NASDAQ:CLSD) Receives Consensus Rating of “Buy” from Brokerages - Defense World
Brokerages Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Price Target at $5.33 - MarketBeat
Here's Why Clearside Biomedical (CLSD) Is a Great 'Buy the Bottom' Stock Now - MSN
Clearside Biomedical's SWOT analysis: innovative eye treatment stock faces pivotal trial - Investing.com
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 11.8% in November - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Upgraded to Hold at StockNews.com - MarketBeat
Clearside Biomedical's SWOT analysis: stock poised for potential breakthrough in wet AMD treatment - Investing.com Nigeria
Clearside Biomedical, Inc. (NASDAQ:CLSD) Short Interest Down 13.6% in November - Defense World
Clearside Biomedical, Inc. (NASDAQ:CLSD) Sees Large Decrease in Short Interest - MarketBeat
Clearside Biomedical (FRA:CLM) Momentum Rank : 5 (As of Nov. 30, 2024) - GuruFocus.com
Clearside showcases eye therapy delivery tech By Investing.com - Investing.com South Africa
Clearside showcases eye therapy delivery tech - Investing.com
Clearside Biomedical Extends Global Footprint with Numerous Presentations at Medical Meetings in Asia, Europe and the United States - The Manila Times
Clearside Biomedical Extends Global Footprint with Numerous - GlobeNewswire
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Rating of "Buy" by Analysts - MarketBeat
Clearside Biomedical, Inc. (NASDAQ:CLSD) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Clearside Biomedical (FRA:CLM) Financial Strength : 4 (As of Sep. 2024) - GuruFocus.com
Crude Oil Brent (SCU24) Quote - The Globe and Mail
Clearside Biomedical’s (CLSD) Buy Rating Reaffirmed at HC Wainwright - Defense World
What is HC Wainwright’s Forecast for CLSD FY2024 Earnings? - Defense World
What is HC Wainwright's Forecast for CLSD FY2024 Earnings? - MarketBeat
Clearside Biomedical's (CLSD) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
Clearside Biomedical (NASDAQ:CLSD) Stock Rating Upgraded by StockNews.com - MarketBeat
All You Need to Know About Clearside Biomedical (CLSD) Rating Upgrade to Buy - MSN
Clearside Biomedical Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Needham & Company LLC Reaffirms Buy Rating for Clearside Biomedical (NASDAQ:CLSD) - Defense World
Clearside Biomedical (NASDAQ:CLSD) Given Buy Rating at HC Wainwright - MarketBeat
Clearside Biomedical Announces Slight Revenue Increase in Third Quarter, Advances Wet AMD Treatment in Clinical Trial - Vision Monday
Earnings call: Clearside Biomedical reports progress in AMD treatment - Investing.com
Finanzdaten der Clearside Biomedical Inc-Aktie (CLSD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.65%
4.62%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):